This content is password protected. To view it please enter your password below:
During her years with CAPT, Kris Schindel provided administrative support for the organization and the Annual Conference. In acknowledgement of her enduring impact and contribution, the annual Kris Schindel Award was established to recognize members of CAPT who have, in some way, contributed significantly to the betterment of the organization. The nomination process, open to all members, is launched in advance of the Annual Conference and is open to all members. The successful nominee is selected by the CAPT board with the award presented during a ceremony at the Annual Conference.
The nomination criteria used to identify potential nominees includes three areas:
Marjorie Morrison is the Executive Director of the Canadian Association for Population Therapeutics. Previously, she served as the Chief Executive Officer of the Canadian Cancer Action Network for 10-years where her work with cancer patient advocacy organizations and Canadian cancer control stakeholders focused primarily in the areas of patient engagement, family caregivers, knowledge translation and health technology assessment. A trained IAP2 public participation practitioner and an CSAE Certified Association Executive, she is an alumnus of the University of Regina and a Master of Health Administration candidate in her second year of graduate studies with the Johnson Shoyama School of Public Policy, Regina, Saskatchewan.
Nancy Dreyer is Chief Scientific Officer and SVP at IQVIA. She focuses on generating real-world evidence for regulators, clinicians, patients and payers through pragmatic trials and non-interventional approaches, and has more than 100 publications research publications. She is a Fellow of both DIA and the Int’l Society of Pharmacoepidemiology. In 2018 she was elected as a member of the PCORI Clinical Trials Methods Advisory Panel and also named to DIA’s Scientific Advisory Committee. She has been a Standing Consultant to the National Football League Health & Safety Executive Committee since 2013. She holds an appointment as Adjunct Professor of Epidemiology at the Gillings School of Global Public Health at the University of North Carolina and is a two-time recipient of PharmaVOICE magazine’s annual list of 100 most influential and inspiring individuals in life sciences.”
Graeme Ball is a Health Economics and Reimbursement Manager with Janssen in Toronto where he is responsible for reimbursement strategy and submissions for oncology products. Prior to joining Janssen, Graeme worked as a Consultant at IQVIA in Tokyo where he managed HEOR projects throughout the Asia-Pacific region including real-world evidence studies, pharmacoeconomic modeling, publications, and quantitative analytics. He has also worked as a Health Economist at the PATH Research Institute in Canada. He holds a BA in Economics, a MA in Economic Policy and Health Economics, and is currently completing a PhD in Health Research Methodology specializing in HTA at McMaster University. His current research focuses on cost-effectiveness methods and survival analysis in oncology.
Fei Fei Liu is the Senior Manager, Health Economics and Outcome Research at Celgene Canada, responsible for designing and supporting the implementation of health economics studies and delivering integrated strategies to ensure the development of real world evidence to support HTA requirements. She has over 15 years’ experience in the pharmaceutical industry, with expertise in clinical research, pricing and reimbursement, health technology assessment and real-world evidence generation and obtained a Bachelor of Science (BSc) degree in Pharmacy in Taiwan and graduated from the University of British Columbia with an MBA degree.
Shanna Trenaman holds a BScH in Chemistry from Acadia University. She completed her BScPharm and MAHSR at Dalhousie University. Shanna is an Accredited Canadian Pharmacy Resident having completed her hospital pharmacy residency at the QEII Health Sciences Centre in affiliation with Dalhousie University. Shanna is licensed pharmacist and practices as a hospital pharmacist in Nova Scotia. Shanna’s doctoral work has been supported by the Nova Scotia Health Research Foundation, the Dalhousie Pharmacy Endowment Fund, the Canadian Society of Hospital Pharmacists’ Foundation, the Canadian Frailty Network, and the Faculty of Graduate Studies at Dalhousie University.
Kimberly Robinson studied Biology at Queen’s University in Kingston, Ontario, graduating with a BScH, in 1988. She then went on to earn an MBA at McGill University in 1990. Kimberly joined the Ontario Public Service in 1990, working in a program area for 4 years and in a policy analysis role for 18 months. In 1996, she joined Janssen-Ortho’s Government and Health Economics Department in a market access strategy and submissions role. During a career with Janssen spanning 18 years, Ms. Robinson held increasingly senior roles in health economics, pricing, government affairs, and as a member of the market access Leadership Team. In 2013, she left Janssen to form PharmaKARe Consulting, a market access and pricing consultancy to the pharmaceutical and medical devices industries.
Luca Pisterzi is the Program Manager for the Toronto Dementia Research Alliance (TDRA), a collaboration among the University of Toronto, Baycrest, CAMH, St. Michael’s Hospital, Sunnybrook, and UHN. Previously he was the Program Manager for the Canadian Partnership for Tomorrow Project (CPTP) at the Canadian Partnership Against Cancer, as well as a Program Lead in Informatics and Analytics at the Ontario Brain Institute (OBI). He received his PhD in biophysics and molecular pharmacology from the Leslie L. Dan Faculty of Pharmacy at the University of Toronto.
Lois Mitchell is a pharmacist with over 25 years of experience in the Canadian pharmaceutical industry. After graduating from the University of Toronto, working 5 years in retail pharmacy, returning to university (MBA, York University), she oined Parke-Davis’ marketing division. After years of increasing responsibilities in marketing, sales, clinical research and market access, Lois joined Janssen’s (J&J) market access division and senior leadership team in 1999, as Director, Communications followed 6-years later as the Director, New Product Reimbursement. She retired in 2014 and continues to consult part-time for the pharmaceutical industry.
Elena Lungu is the Manager of the National Prescription Drug Utilization Information System (NPDUIS) initiative of the Patented Medicine Prices Review Board (PMPRB) and has been with the PMPRB for over a decade where she leads the NPDUIS initiative, with a focus on price, utilization and cost trends in support of policy decisions. Prior to her public service career, she held various consulting positions with Brogan Inc. and holds a Master of Arts in Economics.
Wanrudee Isaranuwatchai is a Research Scientist and Director of the Centre for Excellence in Economic Analysis Research (CLEAR) at St. Michael’s Hospital, as well as an Assistant Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto.
Shoghag Khoudigian is a Senior Consultant in the Health Access and Outcomes, Real World Evidence Solutions at IQVIA (Toronto) and has 4-years of experience in in the pharmaceutical industry in Market Access, and 4 years of experience in academia in Health Technology Assessment (HTA). She holds a PhD in Health Research Methodology, specializing in HTA, at the Programs of Assessment of Technology in Health (PATH) Research Institute (affiliated with McMaster University) and an Honors Bachelor degree in Biology and Pharmacology with a minor in Economics and Biochemistry also from McMaster University.
Laveena Kamboj is the Director, Market Access & Government Affairs, Marketing and Sales with Eisai where she leads the development and implementation of strategies in support of drug reimbursement, including the development and conduct of health economic analyses and outcomes research studies. Currently, she is a PhD Candidate specializing in Health Technology Assessment (HTA) in the Health Research Methodology program at McMaster University and hold an MSc in Health Research Methodology from McMaster University and a BSc in Toxicology from the University of Toronto.
Manjusha Hurry is the Senior Manager in Health Economics focusing on the oncology portfolio at AstraZeneca Canada. She has over 10 years of experience in the field of Health Economics and Health Technology Assessment having previously held positions as Health Economist at Novartis Oncology Canada, Merck Canada or in consulting at the York Health Economics Consortium in the UK. She has completed a Masters in Health Economics at the University of York, UK and recently completed a Masters in Epidemiology from the London School of Hygiene and Tropical Medicine.
Peter Dyrda is the Strategic Access Manager at the Canadian operating company of Janssen Inc. He is responsible for working with the Ontario public drug program in matters related to access and reimbursement of pharmaceuticals. Prior to this role, Peter held various roles at Janssen Inc. focused on health technology assessment (HTA) submissions, health economics, and data generation. Peter holds an MBA with a Healthcare Services Specialization and a BSc in Biology & Pharmacology, both from McMaster University in Hamilton, Ontario